The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.
Much more is known about the APLS than 15 yr ago, but more needs to be done. Clinically, major characteristics of the disorder have been defined, but the course of the disease and its relationship to other disorders, such as systemic lupus erythematosus (SLE), need to be defined. Good progress has been made in standardizing anticardiolipin and, to a lesser extent, LA. However, problems with interlaboratory and inter-assay variation need to be addressed. Doctors are getting a better idea of how to manage these patients with a view to preventing recurrences of thrombosis or pregnancy losses, but prospective studies are still desirable to give more definitive answers. Attention has turned to the pathogenesis of the disorder. It seems likely that antibodies mediate the clinical disorders with which they are associated, but the mechanisms by which this occurs still require further study.
Harris
E N
EN
Department of Medicine, University of Louisville, KY 40292, USA.
D017153:Antibodies, Anticardiolipin / Q000032:analysis; D016736:Antiphospholipid Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000032:analysis; D013927:Thrombosis / Q000517:prevention & control
D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor